Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07224854 · ClinicalTrials.gov registry record

Epigenetic Signature for CRC Early Detection

A clinical trial of Early Detection of Cancer and Cell-free DNA, sponsored by City of Hope Medical Center.

Active
Registry status
500
Enrollment target
1
Study location

NCT07224854 is a study of Early Detection of Cancer and Cell-free DNA that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 500 participants, below the 37,703-participant average among 8 other Early Detection of Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07224854, a study of Early Detection of Cancer and Cell-free DNA, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

The epiCED is a noninvasive blood-based assay designed for early detection of colorectal cancer (CRC) using circulating cell-free DNA (cfDNA) 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) epigenetic markers. This study leverages retrospective, multi-center cohorts of CRC patients and non-cancer controls to discover and validate a robust cfDNA methylation signature. Small-scale sequencing and machine learning-based modeling will be applied to identify a minimal panel of methylation markers that can accurately discriminate CRC from non-cancer individuals, including early-stage disease. The ultimate goal is to develop a clinically practical, noninvasive screening tool that enables population-level early detection and improves patient outcomes.

Study Locations (1)

California

  • City of Hope Nat Medical Ctr - Monrovia

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-06-21
Est. Completion 2026-06-18

Sponsor

City of Hope Medical Center

582 total trials

What the Registry Record Tells You About NCT07224854

The ClinicalTrials.gov registry entry for NCT07224854 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37,703-participant average among 8 other Early Detection of Cancer trials with a reported enrollment target (99% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Early Detection of Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT07224854 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07224854 about?

NCT07224854 is a clinical study titled "Epigenetic Signature for CRC Early Detection". The epiCED is a noninvasive blood-based assay designed for early detection of colorectal cancer (CRC) using circulating cell-free DNA (cfDNA) 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) epigenetic markers. This study leverages retrospective, multi-center cohorts of CRC patients and non...

What is the current status of trial NCT07224854?

This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2024-06-21. Estimated completion is 2026-06-18.

What conditions does trial NCT07224854 study?

This clinical trial studies the following conditions: Early Detection of Cancer, Cell-free DNA, Colorectal Cancer (Diagnosis), Non-cancer Controls, DNA Methylation.

Who is sponsoring clinical trial NCT07224854?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07224854 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Early Detection of Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.